Health Economics & Chronic Pain Policy

The Anxiety-Pain Spiral: What Untreated Emotional Distress Is Quietly Costing Neuropathic Pain Patients

Anxiety and neuropathic pain are not parallel conditions that happen to coexist—they actively amplify one another through shared neurological pathways, creating a cycle that drives up both suffering and healthcare expenditure. New clinical evidence and patient testimony reveal that failing to address anxiety early in the treatment process may be one of the most expensive decisions a chronic pain patient can make. Understanding this relationship is the first step toward breaking it.

Jul 21, 2026

Back in the Game: How Neuropathic Pain Patients Are Rebuilding Their Careers — and What's Making the Difference

Chronic neuropathic pain and anxiety have quietly become one of the leading drivers of reduced workplace productivity and early career disruption in the United States. Yet a growing number of patients — armed with effective treatment plans, informed workplace strategies, and a clearer understanding of their legal protections — are returning to professional life with renewed capability. This article examines five evidence-informed approaches that are making that comeback possible.

Jul 21, 2026

The Price of Waiting: How Delaying Neuropathic Pain Treatment Is Costing Americans Far More Than They Realize

Neuropathic pain affects an estimated 20 million Americans, yet diagnosis and treatment are frequently delayed by months or even years. This data-driven analysis examines the compounding financial and physical toll of postponed care — and makes the case that timely prescription intervention is not only a medical imperative but a sound economic decision.

Jul 21, 2026